FDA Accepts Biologics License Application For Aimovig™ (erenumab) Read more about FDA Accepts Biologics License Application For Aimovig™ (erenumab)
Amgen Announces Webcast of 2017 Second Quarter Financial Results Read more about Amgen Announces Webcast of 2017 Second Quarter Financial Results
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation Read more about Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US Read more about Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label Read more about Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab) Read more about Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma Read more about Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children Read more about FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket Read more about Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket
FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer Read more about FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer
